December 15th, 2015

Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present detailed data from a recently conducted analysis of the long-term extension of its ongoing Phase 1b study of aducanumab at the 10th Clinical Trials on Alzheimer’s Disease Conference meeting in Boston. The webcasts will be live on Thursday, November 2, 2017 at approximately 3:30 p.m. ET (fixed-dose cohorts at up to 36 months) and Saturday, November 4, 2017 at approximately 11:15am ET (titration cohort at up to 24 months). To access the live webcasts, please visit the Investor’s section of Biogen’s website at An archived version of the webcasts will be available following the presentation.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 as one of the world’s first global biotechnology companies by Charles Weissman and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics. We routinely post information that may be important to investors on our website at To learn more, please visit and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.


Karen Jewell, 781-464-2442
Investor Relations

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.